anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a cleaning mask consisting of the following components in parts by mass: 20-50 parts of garden burnet root, 20-50 parts of honeysuckle flower, 10-30 parts of weeping forsythia capsule, 10-30 parts of wild chrysanthemum and 1-3 parts of borneol. The cleaning mask is obtained by mixing the components together and then grinding into powder. The cleaning mask provided by the invention has the effects of controlling oil, cleaning pores, controlling acnes and the like, is suitable for the people who love eating spicy, who love eating fat, sweet, thick and greasy products, and who have accumulated heat in the lung and stomach and exuberance of heart fire. A medicine for closing sores and eliminating carbuncle is used in the formula of the cleaning mask to relieve pain so as to alleviate the symptoms of illnesses, and a medicine for clearing away heat and toxic materials is used for clearing away viscera heat to treat root causes. Meanwhile, by virtue of the effects of controlling oil and cleaning the pores of the cleaning mask, the effect of preventing and controlling regeneration of acnes is achieved. The cleaning mask has the advantages of quick response, obvious effect, high safety, simple and convenient preparation method and the like.
The present invention provides methods for diagnosing neoplasia, assessing the efficacy of therapy to treat neoplasia, assessing the prognosis of a subject who has neoplasia, and treating neoplasia. The present invention also provides a kit for use in detecting neoplasia. The present invention further provides methods for deubiquitinating and/or stabilizing Mdm2 in a cell, and for modulating deubiquitination and/or stability of p53 in a cell. Additionally, the present invention provides a method for identifying a modulator of Mdm2-HAUSP interaction. Also provided is a modulator identified by this method, a pharmaceutical composition comprising the modulator, and use of the modulator in a method of treating neoplasia. The present invention further provides methods for identifying an agent that is reactive with Mdm2 and an agent that is reactive with HAUSP. Also provided are agents identified by these methods. Finally, the present invention provides a complex comprising Mdm2 and HAUSP.
The invention discloses a compound preparation for developing intelligence and benefiting brain and a preparation method thereof. The preparation is composed of needle mushroom, Poria cocos, spine date seed, sharpleaf galangal fruit, taurine, zinc gluconate, starch and magnesium stearate. The method comprises the steps of: extraction and power preparation of raw materials including needle mushroom, Poria cocos, spine date seed, sharpleaf galangal fruit, empty capsule disinfection, and mixing and granulation, etc. The Poria cocos in the formula has the effects of clearing damp, promoting diuresis, benefiting spleen, harmonizing the stomach and tranquilizing the mind; the spine date seed has the effects of nourishing heart, tonifying liver, calming the heart and tranquilizing the mind; and the two medicines are combined to play the role of nourishing heart and tranquilizing the mind. Sharpleaf galangal fruit and Poria cocos are combined to play the role of supplementing spleen and kidney, and tonifying kidney and warming the spleen. In addition, the needle mushroom, zinc gluconate and taurine in the formula can promote mental development, improve the ability of learning and memory, significantly promote the growth of nervous system and proliferation and differentiation of cells, and play an important role during the development of brain nerve cells. Animal function and human test experiments proved that the product provided by the invention has the efficacy of improving memory.
227-P-USO3622 ABSTRACT A stable concentrated aqueous emulsion of perfluorochemical, a phos-pholipid and a triglyceride of fatty acids has been demonstrated which has enhanced stablllty, diminished particle size and heightened tolerance by biological systems. The emulsion has utility as an oxygen transport medium, such as artificial blood. The emulsion can optionally include additional emulsifiers of SURFYNOL? SE surfactant and PLURONIC? P-105 surfactant. The emulsion is produced using an improved emul-sification technique.
Progression of the physical weakness during neoadjuvant therapy (NAT) in patients with esophageal or gastroesophageal junction cancer is a serious problem; however, prehabilitation during NAT has the potential to overcome the unmet need. Nevertheless, systematic reviews on this topic have not been summarized. Therefore, this systematic review aimed to determine prehabilitation's effectiveness, acceptability, and safety during NAT for patients with esophageal or gastroesophageal junction cancer. An electronic search was performed in the MEDLINE, Web of Science, CENTRAL, CINAHL, and PEDro databases. A meta-analysis was conducted to assess the effectiveness of prehabilitation during NAT, along with a descriptive analysis of acceptance and safety. This study analyzed data from three randomized controlled trials (RCTs) and nine non-RCTs involving 664 patients. The meta-analysis of two RCTs demonstrated that prehabilitation during NAT may be more effective than usual care in enhancing tolerance to NAT and grip strength; moreover, one RCT and three non-RCTs revealed that prehabilitation may reduce the risk of postoperative complications. The adherence rates for exercise programs in two RCTs and seven non-RCTs were 55-76%. Additionally, two studies reported a 76% adherence rate for multimodal prehabilitation programs, including exercise, dietary, and psychological care. Six studies reported no serious prehabilitation-related adverse events during NAT. Prehabilitation during NAT may be a safe and beneficial intervention strategy for patients with esophageal or gastroesophageal junction cancer. However, the investigation of strategies to enhance adherence is essential. Furthermore, additional high-quality RCTs are needed to examine the effect of prehabilitation during NAT.
The trial is to investigate the feasibility and efficacy of an artificial intelligence-based patient-tailored intensity-modulated physical training for cancer patients aged over 65 at risk of cancer cachexia. The primary endpoint is simplified cancer CAchexia SCOre (MiniCASCO) reduction. Secondary endpoints include geriatric assessment, physical activity and sarcopenia. This is an open-label, single-arm, single-center phase II investigator-initiated trial. The investigators assume a reduction of MiniCASCO by 10% after trial intervention. Under a statistical power of 80% and a probability of type I error at 0.1 (two-tailed), a minimal of 49 participants will be enrolled. All participants will receive a 12-week supervised physical training and nutritional intervention. Efficacy assessments will be conducted at baseline (week 0), post-intervention (week 12) and follow-up period (week 24). The investigators anticipate that the optimal patient-tailored training program is feasible and improves the symptoms and severity of elderly cancer cachexia. The results may shed light on the debilitating and burdensome condition and provide information on future clinical trials.
An exclusively external use medication lotion can be applied over the infected area whose effect is expedited by the application of a low-frequency electrotherapy that helping the drug penetration into the hypoderma of the infected site. Both sides of the bandage are covered with an pre-prescibed dermophilic medication for treating the infection. A thin film is attached to the bottom surface of the bandage for separation from the lotion. A tape at the top surface of the bandage is to adhere the dressing lotion onto the patient's infected site. A pair of electric conductive layers attached to the bottom of the adhesive tape and corresponding to the upper surface of the bandage. The oscillator sends low-frequency energy onto the electric conductive layers. A button set on the upper surface of the oscillator, controls the oscillator. In addition, a temperature or vibration sensor can be fixed on the bottom of the oscillator for sending signals to the oscillator.
PURPOSE: To illustrate MRI findings in patients with femoral neuropathy following anterior approach total hip arthroplasty (THA).
METHODS: This was a retrospective review of patients who underwent MRI for femoral neuropathy following anterior approach THA between January 1, 2010, and July 1, 2022. Included patients had no preexisting neurologic condition. Clinical and diagnostic data were collected. MRIs were reviewed in consensus by 2 musculoskeletal radiologists.
RESULTS: A total of 115 patient records were reviewed, 17 of which were included in the final analysis (mean age 64 years; 11 females). Study subjects presented with weakness with hip flexion and knee extension and pain and numbness in the femoral nerve distribution. In 7 subjects, the femoral nerve appeared normal. In 5 subjects, the femoral nerve was hyperintense on fluid-sensitive fat-suppressed imaging. In 4 patients, mass effect on the femoral nerve by either ill-defined soft tissue edema (n = 2), seroma (n = 1), or heterotopic ossification (n = 1) was detected. Only 1 patient had a nerve transection. Patients were imaged at a median time of 8 months (range: 1 day to 11 years) following arthroplasty placement. Clinical follow-up was available in 8 patients, of whom half had complete symptomatic resolution and half had partial improvement at a mean follow-up time of 39.3 months (SD 51.1). Of these 8, 1 underwent revision arthroplasty, 1 had removal of hardware, and another had excision of heterotopic ossification.
CONCLUSION: MRI provides a means to directly evaluate the femoral nerve following anterior approach THA in both the immediate and chronic postoperative periods.
Systems and methods for medical monitoring devices are provided. Various embodiments include a monitoring device platform. The platform may adhere to a smartphone and house one or more medical monitoring devices to accommodate for one or more health conditions. The medical monitoring devices may be interchangeable and the types of medical monitoring devices on the platform is customizable. The platform may include Bluetooth® functionality and is compatible with smart phones or other smart devices. Medical information collected by the platform is transmitted to the smart phone for viewing by the user. The medical information may be processed by a machine learning engine and can be used to highlight relevant information within an action plan created by a medical professional. Individual medical devices can slide and lock into the platform and may be used while the phone is in use.
Three studies, consisting of two N-of-1 trials and one crossover study, were used to compare the effect of handwashing with soap and water (intervention) and handwashing with water only (placebo) on phthalate removal from hands. The soap was plain soap, consisting of vegetable oil and sodium hydroxide. First, the investigators recruited one healthy female aged 25 yrs to participate in two N-of-1 trials. In each trial, her hands would be exposed to DEHP and then be treated with either soap intervention or placebo for three times over the course of three days. The first trial started on 15 May 2013. On day one, after the subject prewashed her hands, she allowed her hands to be exposed to a designated amount of DEHP. She then washed them with water only and rinsed them sequentially in three separate polyethylene (PE) bags, each containing 200 mL water to collect DEHP residue. One hour later, the same protocol was followed, except the exposed hands were treated with soap and water instead of water only (Figure 1a). The water rinsing in three separate bags remained the same. The pairs of studies were repeated on two subsequent days (16 and 17 May).

In the second N-of-1 trial, which was also performed over three days (22-24 May), the protocol using the same subject remained the same for all three days, except that the subject underwent intervention first then placebo. The water rinsing remained the same.

A randomized 2 × 2 crossover study was subsequently conducted between June and September 2013. The investigators assigned one group of 7 females and 7 males to perform handwashing with soap and water (intervention) and another group of 7 females and 7 males to perform handwashing with water only (placebo). Briefly, on the first day, the two groups washed their DEHP exposed hands using either soap and water or water only and then rinsed them in a PE bag with 200 mL water to collect DEHP. After 24 hrs, the experiment was crossed-over with the same two groups receiving the opposite treatments.
Disclosed are polypeptides capable of promoting muscle growth comprising the mature myostatin peptide (amino acids 267-375 of SEQ ID NO: 1) truncated at or between amino acid positions 330-350. In particular, polypeptides of the invention are preferably truncated at 330 or 350 and are useful in the treatment of muscle wasting conditions, increasing the muscle mass of a non-human animals and other such uses. Alternatively, mature myostatin proteins having a mutation at position 314 (e.g. the Piedmontese allele ) also having the ability to promote muscle growth, and methods and uses involving these proteins are disclosed. Also disclosed are nucleic acids encoding such proteins and compositions comprising them. (62) Divided out of 502389
The expansion of the aging Veteran population, in addition to the frequent presence of comorbidities (e.g., PTSD and TBI) that exacerbate age-associated cognitive and health declines, has generated substantial interest in interventions that promote brain health in older Veterans. A growing body of evidence shows the positive effects of Brain Health \& Wellness classes on brain health in younger and middle-aged adults, thus training might be able to enhance brain health in older Veterans and offset age-related declines. Such training holds particular promise in enhancing areas of cognition that are especially susceptible to aging processes (e.g. attention and executive control), potentially through multiple mechanistic pathways. It is in many respects a cognitive exercise and may strengthen neural networks involved in such processes. Additionally, there is evidence for further facilitating brain health in other ways related to, for instance, altering the stress response. Currently, there is little information regarding the potential brain health benefits in older adults. As a first step to understanding these potential beneficial effects in Veterans, the aim of the proposed pilot study is to evaluate the acceptability, feasibility and potential efficacy of two Brain Health \& Wellness classes in healthy older Veterans through a randomized, controlled trial.
FIELD: pharmacy. SUBSTANCE: clodronate is crystallized as clodronate disodium tetrahydrate from clodronate disodium an aqueous solution. Formed clodronate disodium tetrahydrate is subjected for dry granulation by compression being crystalline lattice of clodronate disodium tetrahydrate remains to be intact. Then method involves stages of grinding and screening through a sieve and granules of definite size are isolated. If necessary the dried granulated clodronate disodium tetrahydrate is mixed with filling, lubricating and disintegrating agents. Crystallization is performed by addition of partially or completely water-soluble an organic solvent to clodronate disodium tetrahydrate solution where clodronate disodium is difficultly soluble followed by graduate decrease of initial temperature that is above the room one. The stage of wet granulation is excluded in the process. EFFECT: simplified method of preparing, high quality of granules, stable properties of the preparation. 18 cl, 6 ex
Subjects received 3 doses of Aluminium Hydroxide \[Al(OH)3\]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
BACKGROUND: Latines suffer from breast cancer (BC), due to elevated biological and social determinants of health (SDOH) risks. This study compares the effects of different strategies on uptake of cancer genetic services, specifically hereditary cancer risk assessment, genetic counseling, and genetic testing, and risk-based BC care.
DESIGN/METHODS: In Chicago, Illinois, Aim 1 participants are recruited from a federally qualified health center (FQHC) and community venues. For Aim 1, eligible participants: (1) are female; (2) are Latine; (3) are 30+ years old; (4) have personal or family history of BC or cancers with shared hereditary mutations; (5) have at least one SDOH risk; and (6) have not received any cancer genetic services. Participants are randomly assigned to different study arms. Both arms include phone-based sessions, FQHC-based navigation for SDOH, and low- or no-cost cancer genetic services. The educate sessions focus on risk assessment and prevention. The empower sessions focus on risk assessment and equip participants with the skills to share information about FQHC-based cancer genetic services. For Aim 2, eligible participants are: (1) female; (2) network members of Aim 1 participants; and (3) eligible for BC screening based on guidelines recommended by the American Cancer Society (ACS). Primary outcomes include uptake of any cancer genetic services. Analyses will also explore intervention differences by neighborhood context.
DISCUSSION: This is one of the first trials focused on Latines' participation in cancer genetic services and risk-based BC care within the context of SDOH - which has major implications for equity in precision cancer prevention.
Adverse reactions observed with terbutaline are similar to those commonly seen with other sympathomimetic agents. All these reactions are transient in nature and usually do not require treatment.

The following table compares adverse reactions seen in patients treated with terbutaline (0.25 mg and 0.5 mg), with those seen in patients treated with epinephrine injection (0.25 mg and 0.5 mg), during eight double-blind crossover studies involving a total of 214 patients.

Note: Some patients received more than one dosage strength of terbutaline and epinephrine. In addition, there were reports of anxiety, muscle cramps, and dry mouth (less than 0.5%). There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis with terbutaline administration.
Patients in cardiogenic shock receiving a standard management. SGLT2 inhibitor, which are now standard of care in chronic heart failure, in the strict respect of their indications, could be prescribed in the standard management group after hospitalization discharge.
NEW MATERIAL:A Compound of formula I (A is O, S, sulfinyl or sulfonyl; B is lower alkylene; R is H, hydroxymethyl, acyloxymethyl, alkoxycarbonyl or carboxyl). EXAMPLE:4-Carbamoyl-1-tetrahydrofurylimidazolium-5-oleate. USE:Useful as an antitumor agent having powerful inhibitory action on the multiplication of tumorous cells with very low toxicity, and orally administrable. PROCESS:4-Carbamoylimidazolium-5-oleate (or a reactive derivative thereof) is reacted with a compound of formula II (R' is H, acyloxymethyl or alkoxycarbonyl; Y is halogen, lower alkoxyl, trimethylsilyloxy or aroyloxy, etc.) if necessary in the presence of a condensing agent, e.g. trimethylsilyl trifluoromethanesulfonate, and if necessary further hydrolyzed.
Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. The therapeutic agent is not chemically bonded to the water-swellable polymer material. The drug-loaded microbead composition has a water content of less than 1% by weight, based on the total weight of the drug-loaded microbead composition. The drug-loaded microbead composition may be rehydrated to form an embolization composition for use in in embolization therapy. Methods for preparing the drug-loaded microbead compositions and the embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads.
All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.